Choosing the right medication depends on your health needs, effectiveness, side effects, and cost
This indicates that patients may still experience the appetite regulation benefits of GLP-1s, even at lower doses, and the effects may be more gradual and gentler, which could be beneficial for long-term adherence
Fasting glucose and A1C tended to improve in people with diabetes and remained in control in those without diabetes
2022) and GDF8/Activin A inhibitor (K065) is in a Phase 1 trial for obesity and muscular dystrophy (Keros, 2024)
Biocon Biologics (India) has completed Phase 3 trials of a biosimilar semaglutide and announced plans to file for approval in India, the EU, and select emerging markets by mid-2026
Although targeting glutamine metabolism is a promising strategy for cancer therapy, there are many hurdles to be overcome before we develop a clinically effective drug